09 September 2019
Visiongain has published a new pharma report Anti-infective Agents Market Report: Anti-viral Infections, Anti-bacterial Infections, Anti-fungal Infections, Hepatitis Virus Infection, HIV Infection, Pneumonia, Aspergillosis, Methicillin-resistant Staphylococcus Aureus (MRSA), Dermatophytosis, Tuberculosis, Respiratory Virus Infection, Sepsis, Hospital Pharmacies, Retail Pharmacies, Online Sales.
The global anti-infective agents market is estimated to have reached $109bn in 2018 and is expected to grow at a CAGR of 4.2% during the forecast period. In 2018, the hospital pharmacy segment dominated the distribution channel of the anti-infective agents market.
This report profiled the selected companies: Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline (GSK), Merck & Co., Novartis AG, Sanofi SA, Pfizer and other companies.
The lead analyst commented that "The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today. There is an increasing focus to identify and treat infectious diseases. This creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
19 April 2021
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.